Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by O’Reardon, J. P. Articles by Stunkard, A. J. Search for Related Content PubMed Citation Articles by O’Reardon, J. P. Articles by Stunkard, A. J. Eating Disorders Antidepressants Related Article

A Randomized, Placebo-Controlled Trial of Sertraline in the Treatment of Night Eating Syndrome

OBJECTIVE: The authors assessed the efficacy of sertraline in the treatment of night eating syndrome. METHOD: Thirty-four outpatients diagnosed with night eating syndrome were randomly assigned to receive either sertraline (N=17) or placebo (N=17) in an 8-week, double-blind, flexible-dose (50–200 mg/day) study. A mixed effects linear regression model was used to analyze change in the primary outcome measure, Clinical Global Impression (CGI) improvement rating. Secondary outcomes included changes in night eating symptoms, the number of nocturnal awakenings and ingestions, total daily caloric intake after the evening meal, CGI severity ratings, quality of life ratings, and weight. RESULTS: Sertraline was associated with significantly greater improvement than placebo. Twelve subjects in the sertraline group (71%) were classified as having responded (CGI improvement rating 2, indicating much or very much improved) versus only three (18%) in the placebo group. There were also significant improvements in night eating symptoms, CGI severity ratings, quality of life ratings, frequency of nocturnal ingestions and awakenings, and caloric intake after the evening meal. Overweight and obese subjects in the sertraline group (N=14) lost a significant amount of weight by week 8 (mean=–2.9 kg, SD=3.8) compared with overweight and obese subjects receiving placebo (N=14) (mean=–0.3 kg, SD=2.7). CONCLUSIONS: In this 8-week trial, sertraline was effective in the treatment of night eating syndrome and was well tolerated.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A64. [Full Text] [PDF]

This article has been cited by other articles:

				A. Stunkard, K. Allison, and J. Lundgren Issues for DSM-V: Night Eating Syndrome Am J Psychiatry, April 1, 2008; 165(4): 424 - 424. [Full Text] [PDF]

				S. A. Morse, P. S. Ciechanowski, W. J. Katon, and I. B. Hirsch Isn't This Just Bedtime Snacking?: The potential adverse effects of night-eating symptoms on treatment adherence and outcomes in patients with diabetes Diabetes Care, August 1, 2006; 29(8): 1800 - 1804. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us